Lessons from CTLA-4 deficiency and checkpoint inhibition

Area of Science:

• Immunology
• Autoimmunity
• Molecular Biology

Background:

• Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a key negative regulator of immune responses.
• CTLA-4 deficiency in mice results in fatal autoimmunity and widespread tissue destruction.
• Recent discoveries link heterozygous CTLA4 or biallelic LRBA mutations to functional CTLA-4 deficiency and autoimmune conditions.

Purpose of the Study:

• To investigate the role of LRBA in regulating CTLA-4 protein levels.
• To understand the mechanisms behind autoimmune reactions observed in CTLA-4 deficient individuals and those undergoing checkpoint blockade therapy.
• To explore the influence of the microbiota on CTLA-4-regulated antitumor and autoreactive immune responses.

Main Methods:

• Analysis of genetic mutations (heterozygous CTLA4, biallelic LRBA) associated with CTLA-4 deficiency.
• Investigation of CTLA-4 protein levels in regulatory T cells (Tregs) and activated T cells.
• Studies on checkpoint blockade cancer immunotherapy and associated autoimmune responses.
• Exploration of the role of gut microbiota in modulating immune responses.

Main Results:

• LRBA has been identified as a novel regulator of CTLA-4 protein stability in T cells.
• Functional CTLA-4 deficiency, whether genetic or therapy-induced, is strongly associated with autoimmune manifestations.
• The microbiota plays a significant role in modulating both antitumor efficacy and autoimmune reactions driven by CTLA-4.

Conclusions:

• LRBA is essential for maintaining adequate CTLA-4 levels, crucial for immune homeostasis.
• Dysregulation of CTLA-4 function contributes to autoimmunity, highlighting its importance in immune tolerance.
• Microbiota-immune interactions are critical determinants of outcomes in CTLA-4-targeted therapies and autoimmune diseases.